Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.36 |
| ▸ | FPR2 | P25090 | 5/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.31 |
| ▸ | HTR2B | P41595 | 2/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8941341 | 0.95 | CNR2 (0.34) | GABRA1GABRB2 | |
| SCHEMBL8941412 | 0.95 | GABRA1 (0.34) | GABRA1GABRB2FPR2 | |
| SCHEMBL8941564 | 0.94 | FPR2 (0.33) | GABRA1GABRB2FPR2BRD4 | |
| SCHEMBL8941332 | 0.94 | PTPN11 (0.34) | GABRA1GABRB2FPR2 | |
| SCHEMBL8941456 | 0.94 | PTPN11 (0.34) | GABRA1GABRB2FPR2 | |
| SCHEMBL8941428 | 0.94 | PTPN11 (0.34) | GABRA1GABRB2FPR2 | |
| SCHEMBL8941575 | 0.94 | PTPN11 (0.34) | GABRA1GABRB2FPR2 | |
| SCHEMBL8943064 | 0.93 | GABRA1 (0.38) | GABRA1GABRB2FPR2HTR2CHTR2B | |
| SCHEMBL18718327 | 0.92 | CNR2 (0.37) | GABRA1GABRB2FPR2 | |
| SCHEMBL18718322 | 0.91 | FPR2 (0.35) | GABRA1GABRB2FPR2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8187494-B2 | Four- or five-ring liquid crystal compound having lateral fluorine, liquid crystal composition, and liquid crystal display device | JNC CORPORATION (JP) | 2012-05-29 | — | — | US | disclosed |